Cancer chemotherapy and biological response modifiers annual 

About: Cancer chemotherapy and biological response modifiers annual is an academic journal. The journal publishes majorly in the area(s): Cancer & Immunotherapy. It has an ISSN identifier of 0921-4410. Over the lifetime, 131 publications have been published receiving 2440 citations.

Monoclonal antibody therapy for cancer.

Abstract: Our body produces billions of different kinds of antibodies, which are part of the immune system. They have specific archnemeses in the immune system that they target, such as pathogens like diseased cells or viruses. Monoclonal antibodies used in cancer treatment are designed in a lab to target certain antigens — foreign substances in the body — that live on the surface of cancer cells. By targeting those antigens, the antibodies are able to latch onto the cancer cells and act as a “call to arms” for other disease-fighting warriors in the immune system.

Topoisomerase II inhibitors.

Abstract: Topoisomerase II inhibitors are chemicals that inhibit a group of DNA enzymes called type II topoisomerases (topoisomerase IIs). Topoisomerase IIs regulate the structure of DNA and are essential in separating multiple intertwined DNA daughter strands after DNA replication and prior to mitosis. These enzymes resolve knots and tangles in the genetic material by transiently creating and resealing DNA double strand breaks. Thus, topoisomerase IIs are the target of many drugs used in cancer therapy. One category of topoisomerase II inhibitors acts by stabilizing the covalently bound form of topoisomerase II with DNA, resulting in increased topoisomerase II-cross-linked DNA strand breaks. A second category of topoisomerase II inhibitors are referred to as catalytic inhibitors. Inhibitors in this category prevent topoisomerase II from carrying out its required physiological functions, like DNA supercoil relaxation, decatenation (unlinking), and unknotting.